The Beltran lab is focused on understanding mechanisms of treatment resistance in advanced prostate cancer through integration of clinical and molecular features of patients combined with preclinical modeling. We have used genomics and epigenomics to elucidate the molecular mechanisms driving lineage plasticity and evolution towards an androgen receptor (AR) indifferent state. We are developing tissue, imaging, and circulating biomarkers and novel therapeutic strategies for clinical translation. Our mission is to make discoveries that improve the way we manage and treat patients with advanced prostate cancer.